Precision Prevention Strategy to Increase Uptake and Engagement in Lung Cancer Screening and Smoking Cessation Treatment (PRECISE)
Smoking, Smoking Cessation, Tobacco Use Cessation

About this trial
This is an interventional prevention trial for Smoking focused on measuring precision prevention, genetically-informed interventions, lung cancer screening, tobacco treatment, risk feedback
Eligibility Criteria
Inclusion Criteria: CLINICIANS: - Primary care clinician with active caseload in participating clinics PATIENTS: Patient of participating primary care clinician Lung cancer screening naïve Between 50 to 80 years of age, inclusive Currently smoking or quit within past 15 years Cumulative pack years ≥ 20 English-speaking Exclusion Criteria: PATIENTS: Lung cancer diagnosis Current order placed for lung cancer screening Unsuccessful DNA sample analyses
Sites / Locations
- Washington University School of Medicine
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Usual Care
RiskProfile-Clin
RiskProfile-Gen
Annual lung cancer screening with low-dose computed tomography (LDCT) is currently recommended in the U.S. for at-risk patients. Tobacco treatment and cessation is recommended for patients who smoke.
RiskProfile-Clin is a clinically-informed risk feedback tool to activate cancer risk-reducing behaviors.
RiskProfile-Gen is a genetically-informed risk feedback tool to activate cancer risk-reducing behaviors.